Patents by Inventor Chonglan LIN

Chonglan LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20260109714
    Abstract: The present invention discloses a pyrimidine-fused ring compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer, or a solvate thereof. Further, the present invention also discloses a pharmaceutical composition comprising the compound, and use thereof in the preparation of drugs against cancers.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 23, 2026
    Inventors: Tao JIANG, Fusheng ZHOU, Tao LIANG, Chonglan LIN, Lijian CAI, Zhubo LIU, Xiaoming XU, Kai MA, Leitao ZHANG, Zhen LI, Jiong LAN
  • PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20250186456
    Abstract: Provided are a pyrimidine-fused cyclic compound represented by formula (A) having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, a pharmaceutical composition containing the compound, and an application thereof in the preparation of anticancer drugs.
    Type: Application
    Filed: August 31, 2022
    Publication date: June 12, 2025
    Applicants: Genfleet Therapeutics (Shanghai) Inc., ZHEJIANG GEN FLEET THERAPEUTICS CO., LTD.
    Inventors: Tao JIANG, Fusheng ZHOU, Tao LIANG, Leitao ZHANG, Lijian CAI, Zhubo LIU, Qi HUANG, Xiaoming XU, Jichen ZHAO, Yandong LU, Kai MA, Chonglan LIN, Jiong LAN
  • FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20250084078
    Abstract: Disclosed in the present invention is a compound as represented by formula (IA) or formula (IC) or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The definition of each group in the formula is shown in the description for details. Further disclosed are a pharmaceutical composition containing the compound and the use thereof in the preparation of a drug for preventing and/or treating diseases or conditions related to HPK1 activity.
    Type: Application
    Filed: January 3, 2023
    Publication date: March 13, 2025
    Applicants: GENFLEFT THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEFT THERAPEUTICS CO., LTD.
    Inventors: Jichen ZHAO, Fusheng Zhou, Chonglan LIN, Ling PENG, Wan HE, Huabin YANG, Zhen LI, Tao ZHANG, Kai MA, Jiong LAN, Qiang LU
  • AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240360154
    Abstract: Disclosed are an aroyl substituted tricyclic compound, a preparation method therefor and use thereof. Specifically, the aroyl substituted tricyclic compound of the present invention has a structure of formula (C), and has, as a BTK inhibitor, the advantages of high activity, good selectivity and low toxic and side effects.
    Type: Application
    Filed: September 21, 2021
    Publication date: October 31, 2024
    Inventors: Fusheng ZHOU, Tao JIANG, Yingtao LIU, Chonglan LIN, Leitao ZHANG, Zhubo LIU, Kai MA, Wan HE, Xiaoming XU, Lijian FENG, Xiaoling LAN, Qian DING, Qiang LV, Jiong LAN
  • Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
    Patent number: 12054497
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: August 6, 2024
    Assignees: Genfleet Therapeutics (Shanghai)Inc., Zhejiang Genfleet Therapeutics Co., Ltd.
    Inventors: Fusheng Zhou, Tao Jiang, Chonglan Lin, Lijian Cai, Wan He, Jiong Lan
  • FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240182465
    Abstract: A compound having HPK1 inhibitory activity as shown in formula (IA) or (IC), and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and use of same in preparation of a drug for preventing and/or treating diseases or conditions associated with HPK1 activity.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 6, 2024
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Jichen ZHAO, Wan HE, Chonglan LIN, Ling PENG, Huabin YANG, Zhen LI, Xiaoling LAN, Mei GE, Qian DING, Xiang YU, Jiong LAN, Qiang LU
  • SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20240158417
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Application
    Filed: October 17, 2023
    Publication date: May 16, 2024
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO.,LTD.
    Inventors: Fusheng ZHOU, Tao JIANG, Chonglan LIN, Lijian CAI, Wan HE, Jiong LAN
  • FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
    Publication number: 20230203060
    Abstract: Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.
    Type: Application
    Filed: May 27, 2021
    Publication date: June 29, 2023
    Inventors: Fusheng ZHOU, Tao JIANG, Yingtao LIU, Jichen ZHAO, Wan HE, Zhubo LIU, Ling PENG, Lijian CAI, Leitao ZHANG, Chonglan LIN, Huabin YANG, Tao ZHANG, Jiong LAN
  • SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230084095
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Application
    Filed: October 28, 2020
    Publication date: March 16, 2023
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Tao JIANG, Chonglan LIN, Lijian CAI, Wan HE, Jiong LAN